AtriCure Inc (ATRC) - Total Assets
Based on the latest financial reports, AtriCure Inc (ATRC) holds total assets worth $635.44 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AtriCure Inc (ATRC) net assets for net asset value and shareholders' equity analysis.
AtriCure Inc - Total Assets Trend (2001–2024)
This chart illustrates how AtriCure Inc's total assets have evolved over time, based on quarterly financial data.
AtriCure Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
AtriCure Inc's total assets of $635.44 Million consist of 44.0% current assets and 56.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.1% |
| Accounts Receivable | $60.34 Million | 9.9% |
| Inventory | $75.33 Million | 12.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $56.47 Million | 9.3% |
| Goodwill | $234.78 Million | 38.5% |
Asset Composition Trend (2001–2024)
This chart illustrates how AtriCure Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AtriCure Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AtriCure Inc's current assets represent 44.0% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2024, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 38.5% of total assets.
AtriCure Inc Competitors by Total Assets
Key competitors of AtriCure Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.14 Billion |
|
Vizionfocus Inc.
TW:4771
|
Taiwan | NT$6.53 Billion |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
AtriCure Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.87 | 3.62 | 6.24 |
| Quick Ratio | 2.85 | 2.59 | 5.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $223.27 Million | $194.85 Million | $257.60 Million |
AtriCure Inc - Advanced Valuation Insights
This section examines the relationship between AtriCure Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.41 |
| Latest Market Cap to Assets Ratio | 2.37 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | $609.33 Million |
| Market Capitalization | $1.44 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AtriCure Inc's assets at a significant premium (2.37x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: AtriCure Inc's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for AtriCure Inc (2001–2024)
The table below shows the annual total assets of AtriCure Inc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $609.33 Million | -0.75% |
| 2023-12-31 | $613.93 Million | +4.87% |
| 2022-12-31 | $585.45 Million | -4.85% |
| 2021-12-31 | $615.31 Million | -13.89% |
| 2020-12-31 | $714.54 Million | +28.08% |
| 2019-12-31 | $557.88 Million | +56.37% |
| 2018-12-31 | $356.76 Million | +33.27% |
| 2017-12-31 | $267.70 Million | -3.15% |
| 2016-12-31 | $276.42 Million | +1.22% |
| 2015-12-31 | $273.09 Million | +72.40% |
| 2014-12-31 | $158.40 Million | +41.50% |
| 2013-12-31 | $111.95 Million | +245.19% |
| 2012-12-31 | $32.43 Million | -4.22% |
| 2011-12-31 | $33.86 Million | +0.42% |
| 2010-12-31 | $33.72 Million | -3.62% |
| 2009-12-31 | $34.98 Million | -19.34% |
| 2008-12-31 | $43.37 Million | -5.87% |
| 2007-12-31 | $46.07 Million | +17.75% |
| 2006-12-31 | $39.13 Million | -21.81% |
| 2005-12-31 | $50.04 Million | +293.07% |
| 2004-12-31 | $12.73 Million | -13.74% |
| 2003-12-31 | $14.76 Million | -16.08% |
| 2002-12-31 | $17.59 Million | +757.44% |
| 2001-12-31 | $2.05 Million | -- |
About AtriCure Inc
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and li… Read more